CytoSorbents regains Nasdaq minimum bid price compliance

CytoSorbents Corporation (NASDAQ: CTSO) said it received notification from Nasdaq's Listing Qualifications Department on September 22, 2026, that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

The Princeton, N.J.-based medical device company said its common stock closed at or above $1.00 per share for 10 consecutive trading sessions ending September 21, 2026, satisfying the requirement. Nasdaq said the matter is now closed.

The company still faces a separate compliance issue related to the minimum Market Value of Listed Securities requirement under Nasdaq Listing Rule 5550(b)(2), with a compliance deadline of December 28, 2026.

Chief Executive Officer Phillip Chan stated, "We are working towards full compliance with Nasdaq's Capital Market listing requirements by addressing the minimum Market Value of Listed Securities requirement under Nasdaq Listing Rule 5550(b)(2), or satisfying other alternative options, before the December 28, 2026 compliance date."

Chan also cited several business priorities, including driving sales of its CytoSorb product, achieving operating cash flow breakeven in the second half of 2026, and advancing its DrugSorb-ATR device toward FDA regulatory approval.

You May Also Be Interested In

• Anthropic PBC: adjusted operating income increased for the three months ended September 30, 2026 to $2.5 billion
• Osisko Gold names construction VP, loses permitting chief
• Wabtec prices $500M senior notes offering due 2037